After non-myeloablative allogeneic SCT the hematopoiesis is from donor origin (100% donor chimerisme) in almost all cases. The origin of DCs is important in presenting minor antigens to donor T-cells. Autologous or host DCs are capable to directly…
ID
Bron
Verkorte titel
Aandoening
Multiple Myeloma
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Toxicity.
Achtergrond van het onderzoek
N/A
Doel van het onderzoek
After non-myeloablative allogeneic SCT the hematopoiesis is from donor origin (100% donor chimerisme) in almost all cases. The origin of DCs is important in presenting minor antigens to donor T-cells. Autologous or host DCs are capable to directly present minor antigens, while donor DCs can present minor antigens only by cross presentation, which implies active uptake of recipient antigens. As such, host DCs are much better capable to induce graft versus myeloma and graft versus host disease. This concept was confirmed in animal studies and is suggested to be important in humans.
Primary objective:
To evaluate the feasibility of combined DC vaccination and DLI, in the induction of graft-versus-host disease.
Secondary objective:
1. To evaluate the efficacy of combined DC vaccination and DLI to induce a graft-versus-myeloma response;
2. To evaluate the effect of combined DC vaccination and DLI on the immune status of the recipient in correlation with toxicity and response.
Onderzoeksopzet
Dendritic cell vaccination is given at 0, 2 and 4 weeks.
Onderzoeksproduct en/of interventie
Administration of autologeous dendritic cells combined with donor T-cells.
Publiek
Department of Hematology (B02.226),
P.O. Box 85500
H.M. Lokhorst
Utrecht 3508 GA
The Netherlands
+31 (0)88 7557230
h.lokhorst@umcutrecht.nl
Wetenschappelijk
Department of Hematology (B02.226),
P.O. Box 85500
H.M. Lokhorst
Utrecht 3508 GA
The Netherlands
+31 (0)88 7557230
h.lokhorst@umcutrecht.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Multiple myeloma patients with relapsed disease after a non- myeloablative allo-SCT, who have not responded 3 months after a first course of DLI with 1 x 107 T cells/kg body weight;
OR
2. Multiple patients who have received a non myeloablative Allo-SCT from a sibling or MUD donor for relapsed disease after a previous autologous SCT and who have not responded 3 months after a first course of pre-emptive DLI with 1 x 107 T cells/kg (1 x 106 T cells/kg, in case of MUD) cells/kg body weight;
AND
3. Age 18-70 years;
4. Absence of acute GvHD > grade A;
5. Absence of extensive chronic GvHD;
6. WHO performance 0-2;
7. Absence of severe cardiac hepatic, renal, metabolic disease;
8. Written informed consent.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
Not further specified.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL1762 |
| NTR-old | NTR1872 |
| Ander register | 05/263 : UMCU METC |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |